The Role of Timing of Progression and Early Salvage Surgery in Unresectable Hepatocellular Carcinoma Treated with TACE Plus TKIs and PD-1 Inhibitors

被引:0
|
作者
Li, Xingzhi [1 ,2 ]
Tang, Zhihong [1 ]
Pang, Qingqing [1 ]
Wang, Xiaobo [1 ]
Bai, Tao [1 ]
Chen, Jie [1 ]
Wei, Meng [1 ]
Wei, Tao [1 ]
Li, Lequn [1 ]
Wu, Feixiang [1 ,3 ]
机构
[1] Guangxi Med Univ, Canc Hosp, Dept Hepatobiliary Surg, Nanning 530021, Peoples R China
[2] Nanchong Cent Hosp, Clin Coll 2, North Sichuan Med Coll, Dept Hepatobiliary Surg, Nanchong, Peoples R China
[3] Guangxi Med Univ, Key Lab Early Prevent & Treatment Reg High Frequen, Minist Educ, Nanning, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma; salvage surgery; early tumor progression; post-progression survival; real-world; CHEMOEMBOLIZATION; SURVIVAL;
D O I
10.2147/JHC.S481816
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The prognosis of initially unresectable hepatocellular carcinoma (iuHCC) has been improved by TACE with TKIs and PD-1 inhibitors (TTP). However, the role of timing of tumor progression and and early salvage surgery during TTP therapy remains unclear. Patients and Methods: The data of 151 patients who received TTP for iuHCC consecutively between November 2019 and December 2022 were retrospectively analyzed. The X-Tile software was used to determine the optimal threshold of progression timing to differentiate the post-progression survival (PPS) for patients with tumor progression, ultimately yielding 9 months as the optimal cut-off time. Early tumor progression was defined as patients with tumor recurrence (surgical patients) or progressive disease by mRECIST (nonsurgical patients) within 9 months of initial treatment. Accordingly, early salvage surgery was defined as salvage surgery performed within 9 months of the initial treatment. Results: Out of all the patients, 55 (36.4%) patients showed early tumor progression, 33 (34.4%) showed late tumor progression, and 63 (41.7%) showed non-progression. Patients who experienced early tumor progression had a median PPS of 5.2 months, while those with late tumor progression had a median PPS of 16.8 months (P < 0.001). Multivariable analysis revealed a robust independent correlation between early tumor progression and PPS (HR = 3.279, 95% CI: 1.591-6.756; P = 0.001). Patients who received early salvage surgery showed a considerably lower early tumor progression rate when compared with patients who did not receive early surgery (12.5% vs 42.9%, P = 0.002). The multivariable analysis revealed that early salvage surgery was an independent factor influencing early tumor progression (OR = 0.246; 95% CI: 0.078-0.773; P = 0.016). Conclusion: Early tumor progression is associated with worse PPS in patients with iuHCC receiving TTP therapy. Early salvage surgery can further improve patient outcomes by lowering the incidence of early progression.
引用
收藏
页码:1641 / 1652
页数:12
相关论文
共 50 条
  • [21] Deep learning-based CT radiomics predicts prognosis of unresectable hepatocellular carcinoma treated with TACE-HAIC combined with PD-1 inhibitors and tyrosine kinase inhibitors
    Yin, Linan
    Liu, Ruibao
    Li, Wei
    Li, Shijie
    Hou, Xunbo
    BMC GASTROENTEROLOGY, 2025, 25 (01)
  • [22] The safety and efficacy of transarterial chemoembolization (TACE) plus lenvatinib plus programmed cell death protein 1 (PD-1) antibody of advanced unresectable hepatocellular carcinoma
    Zhang, Xiaoyun
    Zhu, Xinrui
    Liu, Chang
    Lu, Wusheng
    Li, Qiu
    Chen, Weixia
    Li, Zhiping
    Lu, Qiang
    Peng, Wei
    Li, Chuan
    Yan, Lvnan
    Yang, Jiayin
    Wen, Tianfu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [23] PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
    Xu, Yongkang
    Fu, Shumin
    Shang, Kai
    Zeng, Jiayu
    Mao, Ye
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [24] The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma
    Wu, Yintao
    Zhu, Jianyong
    Zhang, Hong
    Xia, Nianxin
    CANCER MANAGEMENT AND RESEARCH, 2025, 17 : 239 - 247
  • [25] Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
    Mei, Jie
    Tang, Yu-Hao
    Wei, Wei
    Shi, Ming
    Zheng, Lie
    Li, Shao-Hua
    Guo, Rong-Ping
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [26] The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma
    Liu, Qing-Qing
    Wang, Xiang-Xu
    Ji, Hongchen
    Dou, Qiong-Yi
    Zhang, Hong-Mei
    MEDICAL ONCOLOGY, 2024, 41 (05)
  • [27] Transarterial Chemoembolization Plus Tyrosinkinase Inhibitors and PD-1 Inhibitors for Spontaneously Ruptured Hepatocellular Carcinoma
    Ji, Jie
    Zhou, Chun
    Yan, Le-le
    Ma, Yuan
    Xu, Chuan
    Wang, Fu-an
    Zhou, Wei-Zhong
    Lv, Peng-hua
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2024, 47 (03) : 299 - 309
  • [28] Transarterial Chemoembolization Plus Tyrosinkinase Inhibitors and PD-1 Inhibitors for Spontaneously Ruptured Hepatocellular Carcinoma
    Jie Ji
    Chun Zhou
    Le-le Yan
    Yuan Ma
    Chuan Xu
    Fu-an Wang
    Wei-Zhong Zhou
    Peng-hua Lv
    CardioVascular and Interventional Radiology, 2024, 47 : 299 - 309
  • [29] Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
    Xu Yang
    Bowen Chen
    Yanyu Wang
    Yunchao Wang
    Junyu Long
    Nan Zhang
    Jingnan Xue
    Ziyu Xun
    Linzhi Zhang
    Jiamin Cheng
    Jin Lei
    Huishan Sun
    Yiran Li
    Jianzhen Lin
    Fucun Xie
    Dongxu Wang
    Jie Pan
    Ke Hu
    Mei Guan
    Li Huo
    Jie Shi
    Lingxiang Yu
    Lin Zhou
    Jinxue Zhou
    Zhenhui Lu
    Xiaobo Yang
    Yilei Mao
    Xinting Sang
    Yinying Lu
    Haitao Zhao
    Hepatology International, 2023, 17 : 709 - 719
  • [30] Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
    Yang, Xu
    Chen, Bowen
    Wang, Yanyu
    Wang, Yunchao
    Long, Junyu
    Zhang, Nan
    Xue, Jingnan
    Xun, Ziyu
    Zhang, Linzhi
    Cheng, Jiamin
    Lei, Jin
    Sun, Huishan
    Li, Yiran
    Lin, Jianzhen
    Xie, Fucun
    Wang, Dongxu
    Pan, Jie
    Hu, Ke
    Guan, Mei
    Huo, Li
    Shi, Jie
    Yu, Lingxiang
    Zhou, Lin
    Zhou, Jinxue
    Lu, Zhenhui
    Yang, Xiaobo
    Mao, Yilei
    Sang, Xinting
    Lu, Yinying
    Zhao, Haitao
    HEPATOLOGY INTERNATIONAL, 2023, 17 (03) : 709 - 719